## for Herceptin HYLECTA<sup>™</sup> (trastuzumab and hyaluronidase-oysk)

## **SAMPLE CODING**

## **Breast Cancer**

ТҮРЕ	CODE		DESCRIPTION
Diagnosis: ICD-10-CM	$\begin{array}{c} \texttt{C50.011-C50.019} \\ \texttt{C50.111-C50.119} \\ \texttt{C50.211-C50.219} \\ \texttt{C50.311-C50.319} \\ \texttt{C50.411-C50.419} \\ \texttt{C50.511-C50.519} \\ \texttt{C50.611-C50.619} \\ \texttt{C50.811-C50.819} \\ \texttt{C50.911-C50.919} \end{array}$		Malignant neoplasm of the female breast
	C50.021-C50.029 C50.121-C50.129 C50.221-C50.229 C50.321-C50.329 C50.421-C50.429 C50.521-C50.529 C50.621-C50.629 C50.821-C50.829 C50.921-C50.929		Malignant neoplasm of the male breast
Drug: HCPCS	J9356		Injection, trastuzumab 10 mg and hyaluronidase-oysk
HCPCS Modifier* Note: Beginning July 1, 2023, CMS requires the use of the JZ modifier to indicate there were no units of a drug discarded.	JZ		Zero drug amount discarded/not administered to any patient
Drug: NDC	10-digit	11-digit	
Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.	50242-077-01	50242-0077-01	600 mg/10,000 units
Administration procedures: CPT	96401		Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

\*The JZ modifier is required on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023. For more information on the JZ modifier, visit CMS.gov.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Herceptin HYLECTA™ is a trademark of Genentech, Inc.

Please see full Prescribing Information for Important Safety Information, including BOXED Warnings.

Genentech ©2023 Genentech USA, Inc. So. San Francisco, CA All rights reserved. M-US-00007283(v2.0) 07/23